TSP TruSpine Technologies Plc

TIDMTSP

RNS Number : 6562U

TruSpine Technologies PLC

27 November 2023

27 November 2023

TruSpine Technologies plc

("TruSpine" or the "Company")

Company Update

TruSpine Technologies plc (AQSE: TSP) the medical device company focused on the spinal (vertebral) stabilisation market, provides an update on its business and working capital position.

FDA Update

Further to the announcement on 30 October 2023, the Company continues to be in communication with the U.S. Food and Drug Administration ("FDA") on its 510(k) application for Cervi-LOK as the FDA continue to carry out the substantive review. The Company will update the market on further developments in due course.

Working Capital Position

As previously notified, the Company's working capital position remains weak given the lack of revenue generating operations, however the Company is prudently managing its limited working capital position. The Company is reviewing equity and debt financing options available to it and the Directors fully expect a successful resolution in securing adequate funding to meet the Company's working capital requirements in the near-term.

AGM Update

Further to the announcement on 31 May 2023, the Company intends to reconvene the 2022 Annual General Meeting as soon as practicable.

Proposed Director Appointments Update

Further to the announcement on 18 September 2023, the Company maintains its intention to appoint Victoria Sena and Samuel Ogunsalu, subject to standard regulatory due diligence and securing adequate funding to meet the Company's working capital requirements in the near-term.

US Seller Update

Further to the announcement of 28 April 2022, the Company continues to be in discussions to agree a new redistribution contract with Spartan Medical, Incorporated which the Company expects to sign in due course.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation, and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

 
 TruSpine Technologies Plc                                   Tel: +44 (0)20 7118 0852 
 Laurence Strauss, Chief Executive Officer 
 
 Cairn Financial Advisers LLP (AQSE Corporate Adviser)       Tel: +44 (0)20 7213 0880 
 Liam Murray / Ludovico Lazzaretti 
 Peterhouse Capital Limited (Broker & Financial Adviser) 
                                                             Tel: +44 (0)20 7469 0930 
 Lucy Williams / Duncan Vasey 
 Novus Communications (PR and IR)                            Tel: +44 (0)20 7448 9839 
 Alan Green / Jacqueline Briscoe                              novuscomms@truspine.org 
 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFEIFWLEDSEFF

(END) Dow Jones Newswires

November 27, 2023 02:00 ET (07:00 GMT)

TruSpine Technologies (AQSE:TSP)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

TruSpine Technologies (AQSE:TSP)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024